Clinical efficacy of highly purified urinary FSH versus recombinant FSH in volunteers undergoing controlled ovarian stimulation for in vitro fertilization: a randomized, multicenter, investigator-blind trial
Objective
To compare the efficacy of highly purified human urinary follicle stimulating hormone (HP-hFSH) versus human recombinant follitropin-alpha (rFSH) in volunteers undergoing controlled ovarian stimulation for IVF.
Design
A randomized, controlled, investigator-blind trial.
Setting
Four assisted reproductive technology centers.
Patient(s)
One hundred fifty-two IVF patients.
Intervention(s)
Volunteers, aged 18–39, were randomized to HP-hFSH (n = 76) versus rFSH (n = 76) at a starting dose of 300 IU in down-regulated cycles.
Main Outcome Measure(s)
Number of oocytes, clinical pregnancy rate, and live birth rate with HP-hFSH versus rFSH.
Result(s)
The total IU of gonadotropin used did not differ between the two groups. There was no difference in number of oocytes retrieved with HP-hFSH (mean = 16.3) compared with rFSH (mean = 17.1), confidence interval (CI) of difference = −3.79 to +2.18. Clinical pregnancy rate, as defined by the presence of a gestational sac, was 48.7% (CI = 37.0%–60.4%) with HP-hFSH versus 44.7% (CI = 33.3%–56.6%) with rFSH (CI of difference = −11.9% to +19.8%). Live birth rate was 38.2% (29 of 76) in both groups (CI = 27.2%–50.0%), for a difference between groups of 0.0% (CI of the difference = −15.4% to +15.4%).
Conclusion(s)
There were no statistically significant differences in mean oocyte number, clinical pregnancy rate, or live birth rate between HP-hFSH versus rFSH.
Key Words: IVF, clinical outcome, highly purified urinary FSH, recombinant FSH, pregnancy
To access this article, please choose from the options below
Study funded by Institut Biochimique SA (IBSA), Switzerland.
Dr. Baker has received research support from IBSA. Dr. Adamson is CEO and Shareholder of Advanced Reproductive Care, is a physician owner of Fertility Physicians of Northern California, has received research support from IBSA, and has been a speaker for Ferring Pharmaceuticals. His spouse is also a shareholder in Advanced Reproductive Care. Dr Hoehler has served as a consultant to IBSA, Vital Therapies, Inc., Pioneer Surgical, Kyphon, Cooper Surgical, and Fziomed. Dr. Jones is a consultant for VitalTherapies, Inc., and IBSA, and as of 7/1/07, became an employee of IBSA. Drs. Fujimoto, Kettel, and Soules report no conflicts of interest.
PII: S0015-0282(08)00159-3
doi:10.1016/j.fertnstert.2008.01.064
© 2009 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

